Acadia Pharmaceuticals | ACAD - Current Liabilities


Acadia Pharmaceuticals reported $305.52M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
ALKERMES USD 599.5M 56.06M Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Biogen USD 3B 350.5M Mar/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Cara Therapeutics USD 11.04M 2K Dec/2025
Corcept Therapeutics USD 149.18M 16.9M Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
Eisai JPY 340.25B 47.42B Mar/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Incyte USD 1.49B 25.52M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Moderna USD 2.4B 408M Mar/2026
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Prothena USD 32.52M 8.33M Mar/2026
PTC Therapeutics USD 923.6M 44.82M Mar/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026